Il1α, together with Il1β, belongs to the interleukin-1 family, which has been much more studied in the context of metabolic diseases, and its inhibition is one of the pharmacological strategies being tested as a treatment for type 2 diabetes [51]. This evidence concerns the gene IL1A and metabolic disease.